Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction ended on 08.08.21 with a price of €12.11. With a performance of -6.99%, the BUY prediction by Global_Player finished with a loss. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | 7.711% | 7.711% | 78.583% |
iShares Core DAX® | 1.175% | -0.931% | 13.543% |
iShares Nasdaq 100 | 1.232% | 9.715% | 34.899% |
iShares Nikkei 225® | 1.563% | 3.040% | 8.943% |
iShares S&P 500 | 0.034% | 5.962% | 27.285% |
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
25.04.24
25.04.25
27.04.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
07.12.22
07.12.23
11.12.22